Jacobs Levy Equity Management
FLNA

Jacobs Levy Equity Management’s Filana Therapeutics FLNA Stock Holding History

Jacobs Levy Equity Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-209,080
Closed -$353K – 1063
2026
Q1 		$353K Sell
209,080
-37,907
-15% -$78K ﹤0.01% 866
2025
Q4 		$489K Buy
246,987
+22,329
+10% +$71.5K ﹤0.01% 799
2025
Q3 		$654K Buy
+224,658
New +$517K ﹤0.01% 781
2015
Q1 		– Sell
-1,829
Closed -$26K – 862
2014
Q4 		$26K Buy
+1,829
New +$31.7K ﹤0.01% 804

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

Jacobs Levy Equity Management's FLNA Position: Q2 2026 in Review

Jacobs Levy Equity Management sold out of Filana Therapeutics (FLNA) in Q2 2026, closing a stake of 209,080 shares — an estimated $353K sold.

Jacobs Levy Equity Management first reported a position in FLNA in Q4 2014 and held it in 4 quarters. The position peaked at $654K in Q3 2025. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • Jacobs Levy Equity Management reported no remaining Filana Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 209,080 Filana Therapeutics shares in Q2 2026, an estimated $353K.
  • Jacobs Levy Equity Management first reported a position in Filana Therapeutics in Q4 2014 and held it in 4 quarters.
  • Jacobs Levy Equity Management's Filana Therapeutics position peaked at $654K in Q3 2025.
  • 84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.